Mesoblast Limited (MESO)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mesoblast Limited (‘Mesoblast” or the "Company") (NASDAQ: MESO). The investigation concerns whether Mesoblast and certain of its officers and/or directors have violated federal securities laws.


On August 11, 2020, the FDA released briefing materials for the August 13, 2020, meeting of the Oncologic Drugs Advisory Committee. The meeting was to review Mesoblast's marketing application for Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The FDA briefing documents stated that it was "unclear" if the study results are "relevant" to the proposed indication. Following this news, Mesoblast stock dropped $6.09 per share, or 34.96%, to close at $11.33 on August 11, 2020.


If you are aware of any facts relating to this investigation, or purchased Mesoblast shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.